{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:52:52Z","timestamp":1791928372573,"version":"4.3.4"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T00:00:00Z","timestamp":1595894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40262-020-00924-9","type":"journal-article","created":{"date-parts":[[2020,7,28]],"date-time":"2020-07-28T07:38:12Z","timestamp":1595921892000},"page":"1195-1216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pharmacokinetics\/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK\/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-5878","authenticated-orcid":false,"given":"Markus","family":"Zeitlinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C. P.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Bruggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Felton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Hites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Luque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alasdair P.","family":"MacGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah J. E.","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk E.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Nadrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Standing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o P.","family":"Telles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"W\u00f6lfl-Duchek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Thy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PK\/PD of Anti-Infectives Study Group (EPASG) of the European Society of Clinical Microbiology, Infectious Diseases (ESCMID)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,28]]},"reference":[{"issue":"4","key":"924_CR1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1080\/17460441.2019.1581171","volume":"14","author":"AL Totura","year":"2019","unstructured":"Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discov. 2019;14(4):397\u2013412.","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"924_CR2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498\u2013509.","journal-title":"Lancet Infect Dis"},{"key":"924_CR3","unstructured":"Liverpool Uo. Covid-19 drug interactions. https:\/\/www.covid19-druginteractionsorg\/. Accessed 17 July 2020."},{"key":"924_CR4","unstructured":"WHO. Global research on coronavirus disease (COVID-19). https:\/\/www.whoint\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov. Accessed 17 July 2020."},{"key":"924_CR5","unstructured":"Elsevier. Clinical Pharmacology. https:\/\/www.clinicalpharmacologycom\/. Accessed 17 July 2020."},{"issue":"5","key":"924_CR6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/hep.21136","volume":"43","author":"AH Talal","year":"2006","unstructured":"Talal AH, Ribeiro RM, Powers KA, et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV\/HCV coinfected sustained virological responders from nonresponders. Hepatology. 2006;43(5):943\u201353.","journal-title":"Hepatology"},{"key":"924_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237","author":"X Yao","year":"2020","unstructured":"Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa237(Epub 9 Mar 2020).","journal-title":"Clin Infect Dis."},{"key":"924_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa623","author":"J Fan","year":"2020","unstructured":"Fan J, Zhang X, Liu J, et al. Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients. Clin Infect Dis. 2020. https:\/\/doi.org\/10.1093\/cid\/ciaa623(Epub 21 May 2020).","journal-title":"Clin Infect Dis."},{"key":"924_CR9","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","volume":"6","author":"J Liu","year":"2020","unstructured":"Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.","journal-title":"Cell Discov"},{"issue":"4","key":"924_CR10","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","volume":"3","author":"MGS Borba","year":"2020","unstructured":"Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3(4):e208857.","journal-title":"JAMA Netw Open"},{"key":"924_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31180-6","author":"MR Mehra","year":"2020","unstructured":"Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020. https:\/\/doi.org\/10.1016\/S0140-6736(20)31180-6(Epub 22 May 2020).","journal-title":"Lancet"},{"issue":"25","key":"924_CR12","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2012410","volume":"382","author":"J Geleris","year":"2020","unstructured":"Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411\u20138.","journal-title":"N Engl J Med"},{"key":"924_CR13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016638","author":"DR Boulware","year":"2020","unstructured":"Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2016638(Epub 3 Jun 2020).","journal-title":"N Engl J Med."},{"key":"924_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2022236","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19\u2014 preliminary report. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMc2022236(Epub 10 Jul 2020).","journal-title":"N Engl J Med."},{"issue":"3","key":"924_CR15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","volume":"59","author":"CM Chu","year":"2004","unstructured":"Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252\u20136.","journal-title":"Thorax"},{"issue":"3","key":"924_CR16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bbrc.2004.04.083","volume":"318","author":"N Yamamoto","year":"2004","unstructured":"Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun. 2004;318(3):719\u201325.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"924_CR17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","volume":"67","author":"JF Chan","year":"2013","unstructured":"Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect. 2013;67(6):606\u201316.","journal-title":"J Infect"},{"key":"924_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1834","author":"NJ Mercuro","year":"2020","unstructured":"Mercuro NJ, Yen CF, Shim DJ, et al. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020. https:\/\/doi.org\/10.1001\/jamacardio.2020.1834(Epub 1 May 2020).","journal-title":"JAMA Cardiol."},{"issue":"12","key":"924_CR19","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/2045125317721662","volume":"7","author":"AD Meid","year":"2017","unstructured":"Meid AD, Bighelli I, Machler S, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251\u201364.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"11","key":"924_CR20","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2165\/00003088-200140110-00004","volume":"40","author":"F Pea","year":"2001","unstructured":"Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet. 2001;40(11):833\u201368.","journal-title":"Clin Pharmacokinet"},{"key":"924_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2020.06.22.20137273v1","author":"P Horby","year":"2020","unstructured":"Horby P, Lim WS, Emberson J, Mafham M, Bell J, Linsell L. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. Medrxiv. 2020. https:\/\/doi.org\/10.1101\/2020.06.22.20137273v1.","journal-title":"Medrxiv."},{"issue":"3","key":"924_CR22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0773.1998.tb01457.x","volume":"83","author":"K Villikka","year":"1998","unstructured":"Villikka K, Kivisto KT, Neuvonen PJ. The effect of dexamethasone on the pharmacokinetics of triazolam. Pharmacol Toxicol. 1998;83(3):135\u20138.","journal-title":"Pharmacol Toxicol"},{"issue":"6","key":"924_CR23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/jcpt.12636","volume":"42","author":"J Hahn","year":"2017","unstructured":"Hahn J, Choi JH, Chang MJ. Pharmacokinetic changes of antibiotic, antiviral, antituberculosis and antifungal agents during extracorporeal membrane oxygenation in critically ill adult patients. J Clin Pharm Ther. 2017;42(6):661\u201371.","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"924_CR24","doi-asserted-by":"crossref","first-page":"741.e749","DOI":"10.1016\/j.jcrc.2012.02.013","volume":"27","author":"K Shekar","year":"2012","unstructured":"Shekar K, Fraser JF, Smith MT, Roberts JA. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care. 2012;27(6):741.e749\u2013718.","journal-title":"J Crit Care"},{"issue":"1","key":"924_CR25","first-page":"87","volume":"88","author":"JC Van Stone","year":"1976","unstructured":"Van Stone JC. Hemodialysis and chloroquine poisoning. J Lab Clin Med. 1976;88(1):87\u201390.","journal-title":"J Lab Clin Med"},{"issue":"4","key":"924_CR26","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrneph.2011.12","volume":"7","author":"RF Eyler","year":"2011","unstructured":"Eyler RF, Mueller BA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol. 2011;7(4):226\u201335.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"924_CR27","first-page":"39","volume":"8","author":"MG Vossen","year":"2013","unstructured":"Vossen MG, Thalhammer F. Effects of renal replacement therapy on antimicrobial therapy. Curr Clin Pharmacol. 2013;8(1):39\u201345.","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"924_CR28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000170103","volume":"11","author":"HH Vincent","year":"1993","unstructured":"Vincent HH, Vos MC, Akcahuseyin E, Goessens WH, van Duyl WA, Schalekamp MA. Drug clearance by continuous haemodiafiltration. Analysis of sieving coefficients and mass transfer coefficients of diffusion. Blood Purif. 1993;11(2):99\u2013107.","journal-title":"Blood Purif."},{"issue":"12","key":"924_CR29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","volume":"46","author":"F Pea","year":"2007","unstructured":"Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46(12):997\u20131038.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"924_CR30","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00007691-198609000-00008","volume":"8","author":"A Akintonwa","year":"1986","unstructured":"Akintonwa A, Odutola TA, Edeki T, Mabadeje AF. Hemodialysis clearance of chloroquine in uremic patients. Ther Drug Monit. 1986;8(3):285\u20137.","journal-title":"Ther Drug Monit"},{"issue":"15","key":"924_CR31","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/QAD.0b013e32830e011f","volume":"22","author":"SK Gupta","year":"2008","unstructured":"Gupta SK, Rosenkranz SL, Cramer YS, et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir\/ritonavir in HIV-infected persons requiring hemodialysis. AIDS. 2008;22(15):1919\u201327.","journal-title":"AIDS"},{"issue":"5","key":"924_CR32","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3851\/IMP3210","volume":"23","author":"LM Favie","year":"2018","unstructured":"Favie LM, Murk JL, Meijer A, Nijstad AL, van Maarseveen EM, Sikma MA. Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza. Antiviral Ther. 2018;23(5):457\u201361.","journal-title":"Antiviral Ther"},{"issue":"2","key":"924_CR33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00228-018-2566-6","volume":"75","author":"DL Shuster","year":"2019","unstructured":"Shuster DL, Menon RM, Ding B, et al. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: pharmacokinetic analysis of the phase 3 RUBY-I and RUBY-II trials. Eur J Clin Pharmacol. 2019;75(2):207\u201316.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"924_CR34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00228-011-1137-x","volume":"68","author":"SK Gupta","year":"2012","unstructured":"Gupta SK, Kantesaria B, Glue P. Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol. 2012;68(4):415\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"924_CR35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/107999099313055","volume":"19","author":"A Gotoh","year":"1999","unstructured":"Gotoh A, Hara I, Fujisawa M, et al. Pharmacokinetics of natural human IFN-alpha in hemodialysis patients. J Interferon Cytokine Res. 1999;19(10):1117\u201323.","journal-title":"J Interferon Cytokine Res"},{"issue":"2","key":"924_CR36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1128\/AAC.00626-10","volume":"55","author":"DB Serra","year":"2011","unstructured":"Serra DB, Sun H, Karwowska S, Praestgaard J, Halabi A, Stein DS. Single-dose pharmacokinetics, safety, and tolerability of albinterferon alfa-2b in subjects with end-stage renal disease on hemodialysis compared to those in matched healthy volunteers. Antimicrob Agents Chemother. 2011;55(2):473\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"924_CR37","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787\u201399.","journal-title":"N Engl J Med"},{"issue":"6","key":"924_CR38","first-page":"399","volume":"9","author":"KS Chan","year":"2003","unstructured":"Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003;9(6):399\u2013406.","journal-title":"Hong Kong Med J"},{"key":"924_CR39","unstructured":"WHO. Summaries of evidence from selected experimental therapeutics. https:\/\/www.whoint\/ebola\/drc-2018\/summaries-of-evidence-experimental-therapeuticspdf?ua=1. Accessed 17 July 2020."},{"issue":"11","key":"924_CR40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","volume":"3","author":"A Savarino","year":"2003","unstructured":"Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3(11):722\u20137.","journal-title":"Lancet Infect Dis"},{"key":"924_CR41","unstructured":"Aidsinfo.nih. Guidelines for the use of antiretroviral agents in pediatric HIV infection. https:\/\/www.aidsinfonihgov\/guidelines\/html\/2\/pediatric-arv\/132\/lopinavir-ritonavir. Accessed 17 July 2020."},{"issue":"4","key":"924_CR42","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00003088-199835040-00002","volume":"35","author":"A Hsu","year":"1998","unstructured":"Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275\u201391.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"924_CR43","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/QCO.0000000000000532","volume":"32","author":"FG Hayden","year":"2019","unstructured":"Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019;32(2):176\u201386.","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"924_CR44","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","volume":"14","author":"L Dong","year":"2020","unstructured":"Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58\u201360.","journal-title":"Drug Discov Ther"},{"issue":"3","key":"924_CR45","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12519-020-00343-7","volume":"16","author":"K Shen","year":"2020","unstructured":"Shen K, Yang Y, Wang T, et al. Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement. World J Pediatr. 2020;16(3):223\u201331.","journal-title":"World J Pediatr"},{"issue":"4","key":"924_CR46","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1128\/AAC.02282-12","volume":"57","author":"P Deng","year":"2013","unstructured":"Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother. 2013;57(4):1743\u201355.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"924_CR47","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2165\/00003088-199019050-00003","volume":"19","author":"RJ Wills","year":"1990","unstructured":"Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19(5):390\u20139.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"924_CR48","first-page":"4","volume":"7","author":"YH Jin","year":"2020","unstructured":"Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4.","journal-title":"Mil Med Res"},{"issue":"1","key":"924_CR49","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00498259409043223","volume":"24","author":"I Midgley","year":"1994","unstructured":"Midgley I, Hood AJ, Proctor P, et al. Metabolic fate of 14C-camostat mesylate in man, rat and dog after intravenous administration. Xenobiotica. 1994;24(1):79\u201392.","journal-title":"Xenobiotica"},{"issue":"3","key":"924_CR50","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00535-013-0834-x","volume":"49","author":"H Yuhara","year":"2014","unstructured":"Yuhara H, Ogawa M, Kawaguchi Y, Igarashi M, Shimosegawa T, Mine T. Pharmacologic prophylaxis of post-endoscopic retrograde cholangiopancreatography pancreatitis: protease inhibitors and NSAIDs in a meta-analysis. J Gastroenterol. 2014;49(3):388\u201399.","journal-title":"J Gastroenterol"},{"issue":"11","key":"924_CR51","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1248\/bpb.31.1985","volume":"31","author":"YG Cao","year":"2008","unstructured":"Cao YG, Chen YC, Hao K, Zhang M, Liu XQ. An in vivo approach for globally estimating the drug flow between blood and tissue for nafamostat mesilate: the main hydrolysis site determination in human. Biol Pharm Bull. 2008;31(11):1985\u20139.","journal-title":"Biol Pharm Bull"},{"key":"924_CR52","unstructured":"Kucers\u2019 the use of antibiotics: a clinical review of antibacterial, antifungal, antiparasitic, and antiviral drugs, Seventh Edition, Taylor & Francis Inc; (2. Oktober 2017)"},{"issue":"3","key":"924_CR53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","volume":"30","author":"M Wang","year":"2020","unstructured":"Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269\u201371.","journal-title":"Cell Res"},{"key":"924_CR54","doi-asserted-by":"crossref","first-page":"104786","DOI":"10.1016\/j.antiviral.2020.104786","volume":"178","author":"KT Choy","year":"2020","unstructured":"Choy KT, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.","journal-title":"Antiviral Res"},{"issue":"1","key":"924_CR55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):222.","journal-title":"Nat Commun"},{"issue":"7594","key":"924_CR56","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","volume":"531","author":"TK Warren","year":"2016","unstructured":"Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381\u20135.","journal-title":"Nature"},{"issue":"10236","key":"924_CR57","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569\u201378.","journal-title":"Lancet"},{"issue":"1","key":"924_CR58","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0001-706X(02)00056-6","volume":"83","author":"O Tasanor","year":"2002","unstructured":"Tasanor O, Noedl H, Na-Bangchang K, Congpuong K, Sirichaisinthop J, Wernsdorfer WH. An in vitro system for assessing the sensitivity of plasmodium vivax to chloroquine. Acta Trop. 2002;83(1):49\u201361.","journal-title":"Acta Trop"},{"issue":"17","key":"924_CR59","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1097\/00002030-200111230-00002","volume":"15","author":"A Savarino","year":"2001","unstructured":"Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS. 2001;15(17):2221\u20139.","journal-title":"AIDS"},{"issue":"8","key":"924_CR60","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1128\/AAC.03011-14","volume":"58","author":"AH de Wilde","year":"2014","unstructured":"de Wilde AH, Jochmans D, Posthuma CC, et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother. 2014;58(8):4875\u201384.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1a","key":"924_CR61","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/0002-9343(83)91269-X","volume":"75","author":"AH Mackenzie","year":"1983","unstructured":"Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;75(1a):40\u20135.","journal-title":"Am J Med"},{"issue":"6","key":"924_CR62","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1128\/AAC.00887-10","volume":"55","author":"L Dickinson","year":"2011","unstructured":"Dickinson L, Boffito M, Back D, et al. Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies. Antimicrob Agents Chemother. 2011;55(6):2775\u2013822.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10238","key":"924_CR63","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","volume":"395","author":"IF Hung","year":"2020","unstructured":"Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020;395(10238):1695\u2013704.","journal-title":"Lancet"},{"key":"924_CR64","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.antiviral.2014.02.014","volume":"105","author":"L Oestereich","year":"2014","unstructured":"Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17\u2013211.","journal-title":"Antiviral Res"},{"key":"924_CR65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","volume":"151","author":"SL Bixler","year":"2018","unstructured":"Bixler SL, Bocan TM, Wells J, et al. Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus. Antiviral Res. 2018;151:97\u2013104.","journal-title":"Antiviral Res"},{"issue":"2","key":"924_CR66","doi-asserted-by":"crossref","first-page":"e0005389","DOI":"10.1371\/journal.pntd.0005389","volume":"11","author":"TH Nguyen","year":"2017","unstructured":"Nguyen TH, Guedj J, Anglaret X, et al. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017;11(2):e0005389.","journal-title":"PLoS Negl Trop Dis"},{"key":"924_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.eng.2020.03.007","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing). 2020. https:\/\/doi.org\/10.1016\/j.eng.2020.03.007(Epub 18 Mar 2020).","journal-title":"Engineering (Beijing)."},{"issue":"6","key":"924_CR68","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/jac\/dkw009","volume":"71","author":"EJ Fuchs","year":"2016","unstructured":"Fuchs EJ, Kiser JJ, Hendrix CW, et al. Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients. J Antimicrob Chemother. 2016;71(6):1597\u2013600.","journal-title":"J Antimicrob Chemother"},{"key":"924_CR69","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","volume":"6","author":"X Wang","year":"2020","unstructured":"Wang X, Cao R, Zhang H, et al. The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro. Cell Discov. 2020;6:28.","journal-title":"Cell Discov"},{"issue":"1","key":"924_CR70","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/jmv.22234","volume":"84","author":"MJ Brooks","year":"2012","unstructured":"Brooks MJ, Burtseva EI, Ellery PJ, et al. Antiviral activity of arbidol, a broad-spectrum drug for use against respiratory viruses, varies according to test conditions. J Med Virol. 2012;84(1):170\u201381.","journal-title":"J Med Virol"},{"issue":"5","key":"924_CR71","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5414\/CP201843","volume":"51","author":"Y Sun","year":"2013","unstructured":"Sun Y, He X, Qiu F, et al. Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers. Int J Clin Pharmacol Ther. 2013;51(5):423\u201332.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"7","key":"924_CR72","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.cmi.2020.04.026","volume":"26","author":"N Lian","year":"2020","unstructured":"Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26(7):917\u201321.","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"924_CR73","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/acr.22837","volume":"68","author":"CC Mok","year":"2016","unstructured":"Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res. 2016;68(9):1295\u2013302.","journal-title":"Arthritis Care Res"},{"issue":"12","key":"924_CR74","doi-asserted-by":"crossref","first-page":"18132","DOI":"10.1021\/acsomega.8b01002","volume":"3","author":"A Kumar","year":"2018","unstructured":"Kumar A, Liang B, Aarthy M, et al. Hydroxychloroquine inhibits zika virus NS2B-NS3 protease. ACS Omega. 2018;3(12):18132\u201341.","journal-title":"ACS Omega"},{"issue":"4","key":"924_CR75","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/bcp.12528","volume":"79","author":"L Zheng","year":"2015","unstructured":"Zheng L, Li MP, Gou ZP, et al. A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-alpha variant with peginterferon-alpha-2a in healthy subjects. Br J Clin Pharmacol. 2015;79(4):650\u20139.","journal-title":"Br J Clin Pharmacol"},{"issue":"Pt 3","key":"924_CR76","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1099\/vir.0.061911-0","volume":"95","author":"BJ Hart","year":"2014","unstructured":"Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571\u20137.","journal-title":"J Gen Virol"},{"issue":"12","key":"924_CR77","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1517\/17425255.2015.1094055","volume":"11","author":"H Hegen","year":"2015","unstructured":"Hegen H, Auer M, Deisenhammer F. Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-beta. Expert Opin Drug Metab Toxicol. 2015;11(12):1803\u201319.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"924_CR78","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u2013280.e278.","journal-title":"Cell"},{"issue":"6","key":"924_CR79","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1128\/AAC.00754-20","volume":"64","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Schroeder S, Kleine-Weber H, M\u00fcller MA, Drosten C, P\u00f6hlmann S. Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19. Antimicrob Agents Chemother. 2020;64(6):e00754\u2013e820.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"924_CR80","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00216-008-2054-4","volume":"391","author":"YG Cao","year":"2008","unstructured":"Cao YG, Zhang M, Yu D, Shao JP, Chen YC, Liu XQ. A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study. Anal Bioanal Chem. 2008;391(3):1063\u201371.","journal-title":"Anal Bioanal Chem"},{"key":"924_CR81","unstructured":"Clinical Pharmacology Interaction Report. https:\/\/www.clinicalpharmacology-ip.com\/Forms\/Reports\/intereport.aspx; https:\/\/www.clinicalpharmacology-ip.com\/Forms\/Reports\/intereport.aspx. Accessed 13 Mar 2020."},{"key":"924_CR82","unstructured":"ClinicalTrials.gov. The efficacy of lopinavir plus ritonavir and arbidol against novel coronavirus infection (ELACOI). https:\/\/www.clinicaltrialsgov\/ct2\/show\/NCT04252885?cond=Coronavirus&draw=3&rank=12. Accessed 17 July 2020."},{"issue":"1","key":"924_CR83","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhin.2018.09.005","volume":"101","author":"SY Park","year":"2019","unstructured":"Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect. 2019;101(1):42\u20136.","journal-title":"J Hosp Infect"},{"issue":"1","key":"924_CR84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","volume":"31","author":"F Chen","year":"2004","unstructured":"Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol. 2004;31(1):69\u201375.","journal-title":"J Clin Virol"},{"issue":"1","key":"924_CR85","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5582\/bst.2020.01030","volume":"14","author":"Z Wang","year":"2020","unstructured":"Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64\u20138.","journal-title":"Biosci Trends"},{"key":"924_CR86","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.biopha.2018.01.163","volume":"99","author":"J Xia","year":"2018","unstructured":"Xia J, Rong L, Sawakami T, et al. Shufeng Jiedu Capsule and its active ingredients induce apoptosis, inhibit migration and invasion, and enhances doxorubicin therapeutic efficacy in hepatocellular carcinoma. Biomed Pharmacother. 2018;99:921\u201330.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"924_CR87","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jmv.25729","volume":"92","author":"TT Yao","year":"2020","unstructured":"Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus\u2014a possible reference for coronavirus disease-19 treatment option. J Med Virol. 2020;92(6):556\u201363.","journal-title":"J Med Virol"},{"key":"924_CR88","unstructured":"Registry CCT. A real-world study for lopinavir\/ritonavir (LPV\/r) and emtritabine (FTC)\/tenofovir alafenamide fumarate tablets (TAF) regimen in the treatment of novel coronavirus pneumonia (COVID-19). https:\/\/www.chictrorgcn\/showprojenaspx?proj=48919. Accessed 17 July 2020."},{"issue":"9","key":"924_CR89","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/CM9.0000000000000790","volume":"133","author":"YM Zeng","year":"2020","unstructured":"Zeng YM, Xu XL, He XQ, et al. Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir\/ritonavir plus interferon-alpha, and ribavirin plus lopinavir\/ritonavir plus interferon-alpha in patients with mild to moderate novel coronavirus disease 2019: study protocol. Chin Med J. 2020;133(9):1132\u20134.","journal-title":"Chin Med J"},{"issue":"9","key":"924_CR90","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/cid\/ciz544","volume":"70","author":"YM Arabi","year":"2020","unstructured":"Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and interferon therapy for critically ill patients with Middle East respiratory syndrome: a multicenter observational study. Clin Infect Dis. 2020;70(9):1837\u201344.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"924_CR91","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1473-3099(14)70920-X","volume":"14","author":"AS Omrani","year":"2014","unstructured":"Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014;14(11):1090\u20135.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"924_CR92","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"LJ Stockman","year":"2006","unstructured":"Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.","journal-title":"PLoS Med"},{"issue":"4","key":"924_CR93","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.bbrc.2004.11.128","volume":"326","author":"B Morgenstern","year":"2005","unstructured":"Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. Biochem Biophys Res Commun. 2005;326(4):905\u20138.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"924_CR94","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3851\/IMP3002","volume":"21","author":"UJ Kim","year":"2016","unstructured":"Kim UJ, Won EJ, Kee SJ, Jung SI, Jang HC. Combination therapy with lopinavir\/ritonavir, ribavirin and interferon-alpha for Middle East respiratory syndrome. Antivir Ther. 2016;21(5):455\u20139.","journal-title":"Antivir Ther"},{"issue":"6","key":"924_CR95","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2014.07.026","volume":"44","author":"N Spanakis","year":"2014","unstructured":"Spanakis N, Tsiodras S, Haagmans BL, et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents. 2014;44(6):528\u201332.","journal-title":"Int J Antimicrob Agents"},{"key":"924_CR96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949","author":"PLP Gautret","year":"2020","unstructured":"Gautret PLP, Parola P, Hoang V, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.105949(Epub 20 Mar 2020).","journal-title":"Int J Antimicrob Agents."},{"key":"924_CR97","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","volume":"34","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier JC, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Trav Med Infect Dis. 2020;34:101663.","journal-title":"Trav Med Infect Dis"},{"issue":"24","key":"924_CR98","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","volume":"323","author":"ES Rosenberg","year":"2020","unstructured":"Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state. JAMA. 2020;323(24):2493\u2013502.","journal-title":"JAMA"},{"key":"924_CR99","doi-asserted-by":"crossref","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","volume":"35","author":"M Million","year":"2020","unstructured":"Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Trav Med Infect Dis. 2020;35:101738.","journal-title":"Trav Med Infect Dis"},{"key":"924_CR100","doi-asserted-by":"publisher","unstructured":"Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine in the treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. 2020. https:\/\/doi.org\/10.21203\/rs.3.rs-27223\/v1.","DOI":"10.21203\/rs.3.rs-27223\/v1"},{"issue":"8","key":"924_CR101","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1034\/j.1399-6576.2001.450802.x","volume":"45","author":"JF Bugge","year":"2001","unstructured":"Bugge JF. Pharmacokinetics and drug dosing adjustments during continuous venovenous hemofiltration or hemodiafiltration in critically ill patients. Acta Anaesthesiol Scand. 2001;45(8):929\u201334.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"924_CR102","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-2885.2004.00602.x","volume":"27","author":"PL Toutain","year":"2004","unstructured":"Toutain PL, Bousquet-Melou A. Volumes of distribution. J Vet Pharmacol Ther. 2004;27(6):441\u201353.","journal-title":"J Vet Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00924-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00924-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00924-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T23:12:14Z","timestamp":1627427534000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00924-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,28]]},"references-count":102,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00924-9","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,28]]},"assertion":[{"value":"28 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Markus Zeitlinger, Birgit C.P. Koch, Roger J.M. Bruggemann, Pieter de Cock, Timothy Felton, Maya Christina Hites, Jennifer Le, Sonia Luque, Alasdair Peter Macgowan, Deborah J.E. Marriott, Anouk E. Muller, Kristina Nadrah, David L. Paterson, Joseph F. Standing, Jo\u00e3o Paulo Marochi Telles, Michael Christoph W\u00f6lfl-Duchek, Michael Thy and Jason Roberts declare they have no conflicts of interest associated with the content of the current manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}